Tagged with r

Beaufour IPSEN China Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you to the pharmaceutical industry? I have a very long personal history with China, starting back in my student days. I…

Novo Nordisk China We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those 50% have access to care, and of those 50% get decent care, and finally 50% of those reach their targets.…

Medicilon/MPI Preclinical Research Shanghai You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of people are now returning to China after gaining extensive experience in the US. I personally enjoyed the vast experience that…

Array Liam Condon, Managing Director of Bayer Healthcare China discusses the  government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s main ambitions in China over the next five years.         It has been a rollercoaster four years…

HUYA Bioscience International - China Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this market and building those relationships was a challenge. How did you grow this business in the early days? The early…

Brazil In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as well as its CSR programs. B. Braun has been established in Brazil for more than 40 years, with its headquarters…

COFEPRIS It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge was to familiarize myself with the new agency, which has very wide powers as it regulates many industries. COFEPRIS regulates…

MSD Brasil When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which is the trade name of Montelukast, with the Mont signifying “Montreal” where the product was developed. What will it take…

A.G. (CIF) What was the vision behind the creation of the Camara de la Industria Farmaceutica de Chile (CIF) and what have been the main milestones and achievements? CIF was created in 1953 and was originally composed of all the pharmaceutical laboratories operating in the country. Today CIF is a chamber that…

Pharma Investi Chile As the President of ASILFA what would you say are the main drivers and challenges for the Chilean pharmaceutical industry today? Chile today is moving to implement a new healthcare system. The government is trying to address the inefficiencies of the public system today and to modernize it so that…

R&D-based Pharmaceutical Association Committe You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say that it is easier or harder to tackle today or a decade ago? In my view, the Chinese market is…

China In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your outlook as to how this happened so quickly and what the key factors that revolutionized the industry? During the first…